
Aim To examine the associations between interictal high-sensitivity C-reactive protein (hs-CRP) concentrations and migraine attack frequency and pain intensity. Methods This cross-sectional secondary analysis examined adults with migraine. Monthly attack frequency and pain intensity, assessed using a visual analogue scale (VAS), were obtained retrospectively. Associations were evaluated using Spearman's rank correlation and multiple linear regression adjusted for age, sex, body mass index, migraine type, and current smoking. Hs-CRP concentrations were natural-log transformed for regression analyses. Results The analysis included 81 participants. Median hs-CRP was 1.95 mg/L (interquartile range, 0.62–3.60). Hs-CRP was positively correlated with monthly attack frequency (Spearman's ρ = 0.676, p < 0.001) and pain intensity (Spearman's ρ = 0.568, p < 0.001). In adjusted linear regression, log-transformed hs-CRP remained associated with greater monthly attack frequency (B = 0.835, p < 0.001) and pain intensity (B = 0.591, p < 0.001). Both associations persisted after excluding participants with hs-CRP >10 mg/L, after excluding potentially influential observations, and in analyses using robust standard errors. Conclusion Higher interictal hs-CRP concentrations were associated with greater migraine attack frequency and pain intensity. These exploratory findings should not be interpreted as establishing hs-CRP as a biomarker of migraine severity or disease activity. Given the cross-sectional design, they do not establish temporal or causal relationships.
Introduction Migraine is a prevalent and disabling neurological disorder with subtypes mainly classified and managed based on monthly headache frequency. This study investigates a novel, data-driven clustering approach that uses comprehensive clinical features in addition to headache frequency to further understand migraine subtyping and management. Methods This cross-sectional observational study included participants with a diagnosis of migraine based on self-reported surveys recruited from the Stanford Headache Clinic and surrounding community between 2012 and 2020. This study represents a secondary analysis of a previously collected cohort, incorporating newly added episodic migraine (EM) data alongside existing clinical and demographic variables. This approach extends prior work to refine data-driven migraine subtyping. Participants completed comprehensive surveys capturing clinical, demographic, and treatment-related information. A data-driven clustering approach was applied using hierarchical agglomerative clustering. To determine the optimal number of clusters, visual inspection of the dendrogram, scree plot, and principal component analysis was used. Descriptive statistics and logistic regression models were used to explore clinical characteristics and medication outcomes for each cluster. Results 180 participants were included in the clustering analysis. Two distinct clusters were identified and compared. Cluster 1 ( n = 66; chronic migraine (CM) = 62; EM = 4) had a significantly ( p ≤ 0.001) higher migraine frequency, greater migraine-related disability, higher pain catastrophizing, and more comorbidities (including anxiety, depression, sleep disorders, post-traumatic stress disorder, and somatic symptoms). Cluster 2 ( n = 114; CM = 68; EM = 46) had significantly ( p ≤ 0.001) more years with headache and higher levels of pain self-efficacy. Treatment response differed significantly between clusters for acute medications, with Cluster 2 showing more favorable response rates to triptans and non-steroidal anti-inflammatory drugs ( p ≤ 0.001) and a higher proportion of individuals who indicated that acute medication helped to improve their migraine compared to Cluster 1. Conclusion This study supports the potential use of a comprehensive phenotype-based clustering approach to determine migraine subtypes that correlate with acute treatment outcome.
Objective The Contemporary Prospective Understanding of Migraine Real-world Evidence (CAPTURE) study will provide 2 years of international, prospective, longitudinal data describing the migraine disease course, determinants of disease evolution, and associated treatment patterns. Methods Adults with ≥1 year migraine history who were <50 years of age at onset and currently receiving ≥1 acute and/or preventive migraine medication were enrolled at headache centers (target sample size: n = 1600). Eligible participants were required to have experienced ≥4 monthly headache days in the 3 months before screening. The study population was stratified into 3 cohorts based on monthly headache day frequency during the 1-month screening period: cohort 1: 4 to <8; cohort 2: 8 to <15; cohort 3: ≥15. We collected baseline descriptive demographic and clinical data, including treatment patterns. We will assess migraine evolution over a 24-month follow-up by measuring changes in headache frequency, acute and preventive medication use, patient-reported outcomes (migraine-related disability, quality of life, work productivity, and activity), and migraine-related health care resource utilization. Results As of November 2024, 1062 participants, who were predominantly female and from Europe, were enrolled and included in the full analysis set. Ages were similar across cohorts (mean [range] years, cohort 1: 42.3 [18–72]; cohort 2: 42.2 [18–79]; cohort 3: 43.0 [19–77]). At baseline, >50% of participants were receiving both acute and preventive migraine treatments (cohort 1: 50.0%; cohort 2: 56.4%; cohort 3: 57.6%). Approximately 25% were receiving only acute treatment at baseline (cohort 1: 26.8%; cohort 2: 24.3%; cohort 3: 23.0%), and <20% were receiving only preventive treatment at baseline (cohort 1: 17.3%; cohort 2: 14.0%; cohort 3: 12.8%). Triptans were the most frequent acute treatment at baseline for all cohorts (56.7–59.4%). CGRP mAbs were the most common preventive treatment at baseline for cohorts 1 (20.5%) and 2 (17.8%); onabotulinumtoxinA (22.4%) was the most common in cohort 3. Migraine-related quality-of-life and work productivity decreased proportionally with higher headache frequency. All cohorts reported high migraine-related disability and the presence of interictal burden, with increasing severity from cohort 1 through cohort 3. Similar trends were also observed for anxiety and depression symptoms, and patient-rated disease severity. Cohort 3 also had the lowest acute treatment optimization scores. Conclusion CAPTURE will provide greatly needed international longitudinal data assessing determinants of the evolution of migraine and its associated burden in the context of contemporary treatment patterns. These results will enhance our understanding of predictors of the course of migraine over time.
Background Migraine is a debilitating neurological disorder that imposes a substantial global health burden, with a substantial burden in the Arab world. It frequently coexists with gastrointestinal disorders, particularly irritable bowel syndrome (IBS) and gastroesophageal reflux disease (GERD), potentially reflecting shared gut-brain axis mechanisms. Objective The present study aimed to estimate the prevalence of screening-positive migraine and examine its associations with IBS and GERD, while identifying sociodemographic, dietary, and lifestyle factors associated with screening-positive migraine among adults across Arab countries. Methods A multinational cross-sectional study was conducted between September 2025 and March 2026 using a validated bilingual (Arabic/English) online self-administered questionnaire distributed to adults across Arab countries. The questionnaire assessed sociodemographic characteristics, personal and dietary habits, migraine using the Migraine Screening Questionnaire (MS-Q), IBS according to the Rome IV criteria, and GERD using the GERD Questionnaire. Univariate and hierarchical multivariable logistic regression analyses were performed to identify factors associated with a positive migraine screen. Results Of 3317 participants, 59.7% were female, 46.4% were aged 18–24 years, 77.9% lived in urban areas, and 24.5% had a family history of migraine. Regarding lifestyle factors, 29.7% reported no physical activity, 33.6% slept ≤6 h/night, 44.0% reported low fluid intake (<2 liters/day), 24.9% frequently consumed spicy food, 8.7% ate fast food daily, and 62.2% reported using self-medicated painkillers. A total of 22.4% screened positive for migraine, with 20.5% reporting comorbid IBS and 21.8% reporting comorbid GERD. Common triggers were sleep disturbance, noise, anxiety, and stress while resting, sleep, and self-medicated painkillers were the main relieving factors. Female sex, family history of migraine, IBS, GERD, daily fast-food consumption, and spicy-food intake were independently associated with higher odds of screening-positive migraine. In contrast, higher physical activity levels, adequate sleep duration, more frequent daily meals, and higher family income were associated with lower odds of screening-positive migraine. Conclusion This multinational study found a high prevalence of screening-positive migraine, with strong independent associations with IBS and GERD. Several potential modifiable lifestyle and dietary factors were also associated with screening-positive migraine, highlighting opportunities for integrated gut-brain axis care and targeted public-health interventions promoting regular meals, adequate sleep, physical activity, and reduced fast-food/spicy-food consumption in the region.